News By Tag
News By Place
Follow on Google News
Global Biologics CDMO Market is set to witness a healthy CAGR of 15% to reach $35 billion by 2025
The global biologics CDMO market is driven by the growing biopharmaceutical end market, rapidly expanding pipelines of cell & gene therapies & new vaccines, and significant VC funding.
Huge Potential for Upturn in Outsourcing Ratio
The outsourcing ratio in biologics manufacturing is much less compared to that for small molecules, providing ample opportunity for growth. With the increasingly complex and rapidly evolving biopharma industry, companies are looking for CDMOs who can provide significant regulatory leadership and expertise in all stages from early-stage discovery to commercialization. Moreover, newer technologies like viral vector, mRNA, and cell & gene therapy are where demand exceeds supply, and capabilities may not exist even in large biopharma thereby offering wide scope for outsourcing to CDMOs.
Shifting Market Trend Towards Full-service CDMOs/One-stop-
Large pharmaceutical companies prefer to select a CDMO that also has early-stage development capabilities, as switching costs are significantly higher once cell lines and processes are established. Due to the complexities intrinsic to biologics development, biopharma companies look for a full-service CDMO handling all services, from cell line development through fill-finish and packaging.
"In time, all CDMOs are likely to go digital. Customer demand for high-quality products and information will cause data-driven manufacturing to become the norm." - Lead Scientist, Tier 1 CDMO, USA
Regional Overview: North America is the Largest Biologics CDMO Market
North America is the largest biologics CDMO market while APAC is expected to witness the highest CAGR in the next 5 years, hinged on China. To leverage growth opportunities in APAC, in April 2021, Lonza extended its partnership with Chinese firm Junshi Biosciences to advance and manufacture biologics at its site in Guangzhou, China.
Competitive Landscape Analysis: Global Biologics CDMO Market
The global biologics CDMO market is characterized by a high degree of fragmentation. The leading companies operating in this market are Lonza, Catalent, Samsung Biologics, Fujifilm, Wuxi Biologics, and Boehringer Ingelheim. While some of the other promising market players are Halix, Cobra Biologics, ABL, Biovian, SK Bioscience, IDT, AGC Biologics, Patheon, Abbvie, Novasep, and Emergent Biosolutions.
Get Customized Research Report on Global Biologics CDMO Market @ https://meditechinsights.com/